SPIE Quantum West to Showcase High-Profile Industry Voices
2.2.2021 20:03:00 EET | Business Wire | Press release
SPIE, the international society for optics and photonics, announces the program for its inaugural industry-focused SPIE Quantum West conference 6-11 March. Organized in partnership with the Quantum Economic Development Consortium (QED-C), Quantum West will be held online during the SPIE Photonics West Digital Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005101/en/
Attendance at Quantum West is free to all registered participants of SPIE Photonics West, but registration is required.
The four sessions will provide a wide range of opportunities to learn more about the role of photonics in the development of quantum technology as quantum moves from research and development to engineering products for the commercial marketplace, while building mainstream infrastructures and supply chains. Speakers’ topics include “Quantum Technology as an Enabler,” “Photonics’ Roles in Superconducting Quantum Computing,” and “Building an Industry: Lessons Learned from a Half-Century of Growth in the Photonics Industry.” The four-day event, co-hosted by QED-C Deputy Director Celia Merzbacher and ColdQuanta Executive Chairman and DRS Daylight Solutions Senior Vice President Tim Day, will also include a market report from the Boston Consulting Group.
The international slate of speakers includes Imperial College London’s Peter Knight, who is also a member of the UK’s Quantum Technology Strategic Advisory Board; Andrew Lord, who heads British Telecom’s optical core, access, and quantum research; Google Product Manager Eric Ostby; Toptica’s co-founder and CTO Wilhelm G. Kaenders; Kaitlin R. Moore, a research physicist and principal investigator with SRI International; and Mercedes Gimeno-Segovia, senior director of quantum architecture at PsiQuantum.
A panel discussion on the final day featuring Toptica’s Mark Tolbert, IBM’s Jason Orcutt, Anchored In’s Anke Lohman, and Hamamatsu’s Klea Dhimitri, and moderated by Tim Day, will explore the future of photonics and quantum (“2021 and Beyond”), the challenges of developing a new market, and how photonics will support that.
“We are delighted to partner with the QED-C in launching the first annual Quantum West event,” said SPIE Director of Industry Development Stephen Anderson. “As one of the few industry-oriented quantum technology events to focus on the role of optics and photonics in the emerging market for quantum-enabled devices, Quantum West will play a key role in showcasing the future of the quantum industry and the opportunities it presents for photonics technologies."
“Optics and photonics are critical enabling technologies for many quantum-based applications, including for sensing, communications and computing,” noted QED-C’s Merzbacher. “Quantum West will bring together the photonics and quantum communities to help build the ecosystem and supply chain for the emerging quantum industry.”
To find out more about Quantum West and to register for the event, visit the SPIE Quantum West page.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
About Quantum Economic Development Consortium:
The Quantum Economic Development Consortium (QED-C) is an industry-driven consortium managed by SRI International and established in response to the 2018 National Quantum Initiative Act. Membership includes more than 120 US companies from across the supply chain and more than 40 academic institutions and other stakeholders. The consortium seeks to enable and grow the quantum industry and associated supply chain. For more about QED-C, visit our website or follow us on Twitter @The_QEDC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005101/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom